FDA Brief

Warning letters Drugs

FDA warning letter to

ARG Laboratories, Inc.

High riskIssued Jun 11, 2024Posted Jul 16, 2024Office of Pharmaceutical Quality Operations, Division II

FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.

What happened

FDA inspected ARG Laboratories' Dallas drug manufacturing facility from September 11 to 20, 2023 and reviewed the firm's October 4 response. It found an inadequate quality unit that released lots failing specifications (including a Bullfrog lot failing octocrylene), inadequate identity testing of components such as propylene glycol and octocrylene, no process, cleaning, or water validation, and no stability data to support expiration dates. From product labeling and websites, FDA found Golden Tiger Natural Pain Relieving Cream and Pain Wizard Natural Relief for Muscular & Arthritic Pain were unapproved new drugs and misbranded because their ingredients and claims did not conform to over-the-counter monograph M017.

What FDA found

  1. The quality unit (the group responsible for quality oversight) had no adequate written procedures and did not properly oversee supplier qualification, changes, out-of-specification results, recalls, complaints, or lot release.

    21 CFR 211.22(a) and (d)
  2. The firm did not test each incoming component lot for identity and did not establish the reliability of supplier certificates of analysis, including for propylene glycol and octocrylene.

    21 CFR 211.84(d)(1) and (2)
  3. The firm lacked adequate written production and process controls and did not validate its manufacturing process, cleaning, or water system.

    21 CFR 211.100(a)
  4. The firm lacked stability data to support expiration dates for its drug products.

    21 CFR 211.166(a)
  5. Golden Tiger Natural Pain Relieving Cream and Pain Wizard Natural Relief for Muscular & Arthritic Pain were unapproved new drugs sold without an approved FDA application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  6. The two pain products were misbranded because they did not meet the requirements for nonprescription drugs marketed under section 505G and had no approved application.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee); section 301(a), 21 U.S.C. 331(a)

What FDA wants

FDA tells the firm to correct violations promptly and provide detailed corrective action plans for quality oversight, component testing, validation, and stability, with DEG/EG test results within 30 calendar days. It also tells the firm to address the unapproved new drug and misbranding violations for Golden Tiger and Pain Wizard.

Who should pay attention

  • brands that buy finished over-the-counter topical drugs from this contract manufacturer
  • retailers and distributors selling Golden Tiger or Pain Wizard products
  • quality teams that accept supplier certificates of analysis for high-risk ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk